Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Setipiprant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 known ✓ | Q9Y5Y4 | 19/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 6/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Setipiprant SCHEMBL29358337 | 1.00 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2CYP2C9 | |
| Setipiprant SCHEMBL29355657 | 1.00 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3089983 | 0.89 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3083833 | 0.89 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3083273 | 0.89 | PTGDR2 (0.80) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3091135 | 0.89 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3081699 | 0.86 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3079230 | 0.85 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3085508 | 0.85 | PTGDR2 (0.73) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3083537 | 0.84 | PTGDR2 (0.73) | PTGDR2PTGDRPTGER2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941579-A1 | POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME AND CRTH2 | Amerimmune, LLC (US) | 2022-01-26 | — | — | EP | claimed |
| WO-2020190905-A1 | POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME AND CRTH2 | AMERIMMUNE, LLC (US) | 2020-09-24 | — | — | WO | claimed |
| US-20100234396-A1 | Tetrhydropyridoindole Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-16 | — | — | US | claimed |
| US-7714132-B2 | Tetrahydropyridoindole derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-05-11 | — | — | US | claimed |
| EP-1725553-B1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-07 | — | — | EP | claimed |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | claimed |
| EP-1725553-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-11-29 | — | — | EP | claimed |
| WO-2005095397-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | claimed |
| US-20230330062-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | INST NAT SANTE RECH MED (FR) | 2023-10-19 | — | — | US | disclosed |
| US-20230330062-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | INST NAT SANTE RECH MED (FR) | 2023-10-19 | — | — | US | disclosed |
| US-11559513-B2 | PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-01-24 | — | — | US | disclosed |
| EP-3941579-A1 | POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME AND CRTH2 | Amerimmune, LLC (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020190905-A1 | POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME AND CRTH2 | AMERIMMUNE, LLC (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20200261413-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | UNIVERSITÉ PARIS CITÉ (FR) | 2020-08-20 | — | — | US | disclosed |
| US-20100234396-A1 | Tetrhydropyridoindole Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-16 | — | — | US | disclosed |
| US-7714132-B2 | Tetrahydropyridoindole derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-05-11 | — | — | US | disclosed |
| EP-1725553-B1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | disclosed |
| EP-1725553-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005095397-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234396-A1 | Tetrhydropyridoindole Derivatives | TPH2, TPH1, HTR5A | PTGDR2 170/4885PTGDR 135/4885PTGER2 351/4885 |
| US-20230330062-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | PTGDR2, PTGDR, PTGIR | PTGDR2 1/4885PTGDR 2/4885PTGER2 9/4885 |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | TPH2, TPH1, HTR2C | PTGDR2 154/4885PTGDR 119/4885PTGER2 213/4885 |
| US-20200261413-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | PTGDR, PTGDR2, PTGIR | PTGDR2 2/4885PTGDR 1/4885PTGER2 9/4885 |
| US-11559513-B2 | PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus | PTGDR, PTGDR2, PTGIR | PTGDR2 2/4885PTGDR 1/4885PTGER2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.